Closed |
S0022 |
Cis/Doc/RT followed by Consolidation Doc in NSCLC; Stage IIIB |
3/15/2001 |
2/1/2003 |
33% |
|
|
Closed |
S0023 |
Cis/VP-16/RT/Consol. Doc followed by ZD1839/Placebo /IIIA & selected IIIB NSCLC |
6/15/2001 |
4/15/2005 |
74% |
|
Published
|
Closed |
S0025 |
OVARIAN |
2/15/2003 |
8/15/2003 |
5% |
|
|
Closed |
S0026 |
IFN & Thalidomide in Disseminated Malignant Melanoma |
11/1/2001 |
5/1/2003 |
62% |
|
Published
|
Closed |
S0027 |
Vinorel/Doc/Adv NSCLC/Age >=70 PS 0-1/PS 2 any age; Selected IIIB & IV |
9/1/2001 |
7/1/2003 |
100% |
|
Published
|
Closed |
S0028 |
Advanced Bladder |
7/1/2001 |
12/15/2006 |
81% |
|
|
Closed |
S0029 |
ADVANCED: Docetaxel for Metastatic Breast Cancer |
8/1/2001 |
6/15/2005 |
34% |
|
|
Closed |
S0030 |
COLORECTAL |
2/1/2003 |
2/1/2005 |
48% |
|
Published
|
Closed |
S0031 |
Advanced Bladder |
2/15/2001 |
10/15/2002 |
56% |
|
Published
|
Closed |
S0032 |
Advanced Prostate |
12/1/2001 |
6/1/2005 |
48% |
|
Published
|
Closed |
S0033 |
Gastrointestinal Stromal Tumor |
12/15/2000 |
9/1/2001 |
100% |
|
Published
|
Closed |
S0101 |
ESOPHAGEAL |
4/15/2001 |
2/1/2003 |
100% |
|
Published
|
Closed |
S0102 |
ADVANCED: Doxetaxel/Vinorelbine/Filgrastim for HER-2 Neg Stage IV Breast Cancer |
5/1/2001 |
1/1/2004 |
100% |
|
Published
|
Closed |
S0106 |
Phase III Starndard + Mylotarg vs. Standard + Daunomycin/Ara-C for AML Under Age 61 |
5/15/2004 |
8/20/2009 |
93% |
|
Published
|
Closed |
S0107 |
PANCREAS |
7/1/2001 |
6/1/2003 |
100% |
|
Published
|
Closed |
S0108 |
NON-HODGKIN'S: Bevacizumab For Relapsed Aggressive NHL |
4/15/2001 |
12/1/2004 |
87% |
|
Published
|
Closed |
S0109 |
Advanced Renal |
5/1/2001 |
2/1/2002 |
100% |
|
Published
|
Closed |
S0111 |
Advanced Prostate |
6/15/2001 |
11/15/2003 |
100% |
|
Published
|
Closed |
S0112 |
Elderly AML |
8/1/2001 |
4/1/2003 |
100% |
|
Published
|
Closed |
S0114 |
EGFRvIII Peptide Vaccine |
11/1/2002 |
6/1/2006 |
47% |
|
|